XOMA Quote, Financials, Valuation and Earnings

Gossamer Bio, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -362.73%. XOMA Royalty Corp.'s return on equity of 17.31% beat Gossamer Bio, Inc.'s return on equity of -615%.

XOMA Royalty Corp. has a consensus price target of $65.75, signalling upside risk potential of 157.54%. On the other hand Gossamer Bio, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 1238.13%. Given that Gossamer Bio, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Gossamer Bio, Inc. is more attractive than XOMA Royalty Corp..

XOMA Royalty Corp. has a beta of 0.855, which suggesting that the stock is 14.461% less volatile than S&P 500. In comparison Gossamer Bio, Inc. has a beta of 1.931, suggesting its more volatile than the S&P 500 by 93.136%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Gossamer Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Gossamer Bio, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are smaller than Gossamer Bio, Inc. quarterly revenues of $13.3M. XOMA Royalty Corp.'s net income of $10.3M is higher than Gossamer Bio, Inc.'s net income of -$48.2M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 34.25x while Gossamer Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 8.88x versus 2.19x for Gossamer Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Mirum Pharmaceuticals, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -3.85%. XOMA Royalty Corp.'s return on equity of 17.31% beat Mirum Pharmaceuticals, Inc.'s return on equity of -8.84%.

XOMA Royalty Corp. has a consensus price target of $65.75, signalling upside risk potential of 157.54%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $122.36 which suggests that it could grow by 32.59%. Given that XOMA Royalty Corp. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe XOMA Royalty Corp. is more attractive than Mirum Pharmaceuticals, Inc..

XOMA Royalty Corp. has a beta of 0.855, which suggesting that the stock is 14.461% less volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.821%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $148.9M. XOMA Royalty Corp.'s net income of $10.3M is higher than Mirum Pharmaceuticals, Inc.'s net income of -$5.7M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 34.25x while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 8.88x versus 9.17x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -304.24%. XOMA Royalty Corp.'s return on equity of 17.31% beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.

XOMA Royalty Corp. has a consensus price target of $65.75, signalling upside risk potential of 157.54%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 82.95%. Given that XOMA Royalty Corp. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe XOMA Royalty Corp. is more attractive than Recursion Pharmaceuticals, Inc..

XOMA Royalty Corp. has a beta of 0.855, which suggesting that the stock is 14.461% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. XOMA Royalty Corp.'s net income of $10.3M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 34.25x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 8.88x versus 22.04x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of --. XOMA Royalty Corp.'s return on equity of 17.31% beat Rezolute, Inc.'s return on equity of -67.99%.

XOMA Royalty Corp. has a consensus price target of $65.75, signalling upside risk potential of 157.54%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.75 which suggests that it could grow by 47.98%. Given that XOMA Royalty Corp. has higher upside potential than Rezolute, Inc., analysts believe XOMA Royalty Corp. is more attractive than Rezolute, Inc..

XOMA Royalty Corp. has a beta of 0.855, which suggesting that the stock is 14.461% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.658%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are larger than Rezolute, Inc. quarterly revenues of --. XOMA Royalty Corp.'s net income of $10.3M is higher than Rezolute, Inc.'s net income of -$22.8M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 34.25x while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 8.88x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.